Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Accumulated Expenses: 2018-2025

Historic Accumulated Expenses for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to $8.2 million.

  • Whitehawk Therapeutics' Accumulated Expenses fell 41.80% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year decrease of 41.80%. This contributed to the annual value of $14.6 million for FY2024, which is 2.38% up from last year.
  • Per Whitehawk Therapeutics' latest filing, its Accumulated Expenses stood at $8.2 million for Q3 2025, which was up 51.67% from $5.4 million recorded in Q2 2025.
  • Whitehawk Therapeutics' Accumulated Expenses' 5-year high stood at $14.9 million during Q4 2022, with a 5-year trough of $677,891 in Q2 2021.
  • Moreover, its 3-year median value for Accumulated Expenses was $10.8 million (2023), whereas its average is $11.1 million.
  • Per our database at Business Quant, Whitehawk Therapeutics' Accumulated Expenses surged by 1,201.21% in 2021 and then slumped by 60.61% in 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Accumulated Expenses (Quarterly) stood at $8.7 million in 2021, then soared by 71.46% to $14.9 million in 2022, then fell by 4.13% to $14.3 million in 2023, then rose by 2.38% to $14.6 million in 2024, then tumbled by 41.80% to $8.2 million in 2025.
  • Its last three reported values are $8.2 million in Q3 2025, $5.4 million for Q2 2025, and $8.6 million during Q1 2025.